Articles Tagged With: aspirin
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Apixaban vs. Aspirin for Subclinical Atrial Fibrillation
A randomized controlled trial of apixaban vs. low-dose aspirin therapy for subclinical atrial fibrillation detected by implanted electrophysiologic devices showed that apixaban is associated with fewer strokes, but more major bleeding episodes compared to aspirin.
-
Reconsidering Aspirin Therapy for Elderly Patients
A post-hoc analysis of the ASPREE trial revealed that in presumably healthy elderly subjects, taking low-dose aspirin daily over three years was associated with a significant drop in hemoglobin and ferritin levels vs. placebo, even when patients with major bleeding events were excluded.
-
Reconsidering Aspirin Therapy for Elderly Patients
A post-hoc analysis of the ASPREE trial revealed that in presumably healthy elderly subjects, taking low-dose aspirin daily over three years was associated with a significant drop in hemoglobin and ferritin levels vs. placebo, even when patients with major bleeding events were excluded.
-
Effectiveness and Safety of Low-Dose Aspirin to Prevent Preterm Preeclampsia
An aspirin dosage of 150 mg to 162 mg per day, when started in the first trimester of pregnancy, was linked to a decreased risk of preterm preeclampsia compared to an aspirin dosage of 75 mg to 81 mg per day.
-
Long-Term Maintenance Therapy After Percutaneous Coronary Intervention
An extended six-year follow-up of the HOST-EXAM study revealed the consistent benefit of the primary endpoint of fewer major cardiovascular events and less bleeding with clopidogrel vs. low-dose aspirin monotherapy in post-percutaneous coronary intervention patients who were on dual antiplatelet therapy for one year.
-
Is There a Role for Aspirin for the Treatment of Acute Respiratory Distress Syndrome?
Based on this randomized, placebo-controlled Phase II trial, further research still is required to determine if aspirin therapy is beneficial for the treatment of acute respiratory distress syndrome, since aspirin did not improve oxygenation index or other respiratory physiologic markers.
-
Updated Aspirin Guidance from the U.S. Preventive Services Task Force
The authors of new recommendations advise avoiding initiating aspirin for primary prevention of cardiovascular disease in adults age 60 years or older, individualizing decisions based on characteristics and preferences for patients.
-
Panel Backs Away from Aspirin for Cardiovascular Disease Primary Prevention
Experts say patients age 60 years and older should not start taking the drug to prevent a first stroke or heart attack.